The content on this site is intended for healthcare professionals only
Dr Turner presents, at a press conference at ASCO 2015, the phase III registration study PALOMA-3, which reports that adding the investigational targeted agent palbociclib to standard hormonal therapy (fulvestrant) more than doubled the duration of disease control, delaying disease progression by roughly five months in women with previously treated, hormone receptor-positive, human epidermal growth factor receptor 2 negative (HR /HER2-) advanced breast cancer.
Read the news article and watch the interview for more.
Targeted therapies associated with increased risk for and incidence of thrombosis in the treatment of breast cancer
HER3-DXd demonstrates similar efficacy compared to multi-agent chemotherapy in high-risk HR-positive/HER2-negative eBC
ESMO 2024: Optimising the personalisation of prostate cancer treatment
Trastuzumab deruxtecan effective against brain metastases in HER2-positive breast cancer
Preoperative endocrine therapy in premenopausal women leads to sparing chemotherapy in additional patients
OncoAlert round up July 28th to August 3rd, 2023
Adding ribociclib to endocrine therapy shows an improvement in invasive disease-free survival in HR+/HER2 BC patients
SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer
Spindle cell lesions of the breast
